Nivolumab plus chemotherapy in Asian people with advanced or recurrent stomach or gastroesophageal junction cancer (ATTRACTION-4 study): a plain language summary

초록

Plain Language Summary: What is this summary about? This is a plain language summary of a study called ATTRACTION-4. In this study, researchers looked at the effects of a medication called nivolumab, which can boost anti-tumor immunity. Asian people with cancer of the stomach or the junction where the food pipe joins the stomach (called gastroesophageal junction) that had spread to other parts of the body (called advanced cancer) or came back after surgery (called recurrent cancer), and could not be removed by surgery joined the study. Only people whose cancer did not produce a protein called HER2 (known as HER2-negative cancer) could take part in the study. The researchers wanted to know whether adding nivolumab to standard chemotherapy (a medicine that kills cancer cells) could help to treat people with advanced or recurrent stomach or gastroesophageal junction cancer better than standard chemotherapy alone. They also wanted to know what side effects people taking the treatments had. People with advanced or recurrent stomach or gastroesophageal junction cancer who took part in the ATTRACTION-4 study were randomly divided into two groups. People in the first group were given intravenous infusion of nivolumab plus chemotherapy. People in the second group were given intravenous placebo plus chemotherapy. The doctors could choose between two standard chemotherapies, either oxaliplatin plus S-1 (also known as SOX) or oxaliplatin plus capecitabine (also known as CAPOX). Both options were standard of care for this type of cancer at the time of the study. What are the key takeaways? People receiving nivolumab plus chemotherapy lived longer without their cancer growing or spreading to other parts of the body (called progression-free survival) than people receiving placebo plus chemotherapy. The length of time people lived after starting the study treatments was similar in both groups, with median survival times of approximately 17 months. Many patients in the placebo plus chemotherapy group started nivolumab after their cancer had progressed. This may have helped to improve their overall survival. More people receiving nivolumab plus chemotherapy had their tumors shrink or disappear. The tumors continued to respond to treatment without growing or spreading for a longer time in people receiving nivolumab plus chemotherapy. Adding nivolumab to standard chemotherapy did not result in any additional mental or physical health burden. During the study, some participants developed side effects related to the treatment. The three most common side effects were peripheral sensory neuropathy (a condition associated with impaired nerve function leading to numbness or pain in the hands or feet in particular), decreased appetite, and nausea (feeling sick) in both groups. The people receiving nivolumab plus chemotherapy had side effects that were similar to the known side effects of this treatment. What do the results mean? This study was designed to assess if the addition of nivolumab to standard chemotherapy might have a positive impact for Asian people with advanced or recurrent stomach or gastroesophageal junction cancer that did not have the HER2 protein. This is a type of cancer for which there are few treatments available. The study showed that nivolumab plus chemotherapy increase the length of time people with advanced or recurrent stomach cancer live without their cancer getting worse. Nivolumab plus chemotherapy has been approved as first-line treatment for advanced stomach cancer in more than 50 countries, including the United States, Japan, South Korea, and Taiwan. Clinical trial number: NCT02746796. © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

키워드